These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 1996556)

  • 41. Desmopressin therapy to assist the functional identification and characterisation of von Willebrand disease: differential utility from combining two (VWF:CB and VWF:RCo) von Willebrand factor activity assays?
    Favaloro EJ; Thom J; Patterson D; Just S; Dixon T; Koutts J; Baccala M; Rowell J; Baker R
    Thromb Res; 2009 Apr; 123(6):862-8. PubMed ID: 19064279
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Laboratory diagnosis and monitoring of desmopressin treatment of von Willebrand's disease by flow cytometry.
    Giannini S; Mezzasoma AM; Leone M; Gresele P
    Haematologica; 2007 Dec; 92(12):1647-54. PubMed ID: 18055988
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Desmopressin enhances the binding of plasma von Willebrand factor to collagen in plasmas from normal dogs and dogs with type I von Willebrand's disease.
    Johnstone IB
    Can Vet J; 1999 Sep; 40(9):645-8. PubMed ID: 10495907
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Von Willebrand's disease: case report and review of literature.
    Echahdi H; El Hasbaoui B; El Khorassani M; Agadr A; Khattab M
    Pan Afr Med J; 2017; 27():147. PubMed ID: 28904675
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Managing patients with von Willebrand disease type 1, 2 and 3 with desmopressin and von Willebrand factor-factor VIII concentrate in surgical settings.
    Michiels JJ; van Vliet HH; Berneman Z; Schroyens W; Gadisseur A
    Acta Haematol; 2009; 121(2-3):167-76. PubMed ID: 19506363
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Native multimer analysis of plasma and platelet von Willebrand factor compared to denaturing separation: implication for the interpretation of satellite bands.
    Hohenstein K; Griesmacher A; Weigel G; Golderer G; Ott HW
    Electrophoresis; 2011 Jun; 32(13):1684-91. PubMed ID: 21647922
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Type 2B von Willebrand's disease due to Val1316Met mutation. Heterogeneity in the same sibship.
    Rendal E; Penas N; Larrabeiti B; Pérez A; Vale A; López-Fernández MF; Batlle J
    Ann Hematol; 2001 Jun; 80(6):354-60. PubMed ID: 11475150
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Increased amounts of von Willebrand factor are bound to microparticles after infusion of desmopressin.
    Trummer A; Haarmeijer B; Werwitzke S; Wermes C; Ganser A; Budde U; Tiede A
    Haemophilia; 2013 Mar; 19(2):236-41. PubMed ID: 23051555
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Laboratory and molecular characteristics of recessive von Willebrand disease type 2C (2A subtype IIC) of variable severity due to homozygous or double heterozygous mutations in the D1 and D2 domains.
    Michiels JJ; Gadisseur A; van der Planken M; Schroyens W; Berneman Z
    Acta Haematol; 2009; 121(2-3):111-8. PubMed ID: 19506357
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Mild forms of von Willebrand disease: diagnosis and management.
    Federici AB
    Curr Hematol Rep; 2003 Sep; 2(5):373-80. PubMed ID: 12932308
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evaluation of desmopressin effects on haemostasis in children with congenital bleeding disorders.
    Hanebutt FL; Rolf N; Loesel A; Kuhlisch E; Siegert G; Knoefler R
    Haemophilia; 2008 May; 14(3):524-30. PubMed ID: 18284449
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Subunit composition of plasma von Willebrand factor. Cleavage is present in normal individuals, increased in IIA and IIB von Willebrand disease, but minimal in variants with aberrant structure of individual oligomers (types IIC, IID, and IIE).
    Zimmerman TS; Dent JA; Ruggeri ZM; Nannini LH
    J Clin Invest; 1986 Mar; 77(3):947-51. PubMed ID: 3485111
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Diagnosis and management of von Willebrand disease].
    Higasa S; Tokugawa T; Sawada A
    Rinsho Ketsueki; 2018; 59(10):2222-2232. PubMed ID: 30305529
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Multimeric analysis of von Willebrand factor before and after desmopressin acetate (DDAVP) administration intravenously and subcutaneously in male beagle dogs.
    Kraus KH; Turrentine MA; Johnson GS
    Am J Vet Res; 1987 Sep; 48(9):1376-9. PubMed ID: 3499101
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Study of endothelial t-PA and vWf in normal subjects and in von Willebrand's disease.
    Wieczorek I; Ludlam CA; MacGregor IR
    Blood Coagul Fibrinolysis; 1994 Jun; 5(3):329-34. PubMed ID: 8075304
    [TBL] [Abstract][Full Text] [Related]  

  • 56. PFA-100 monitoring of von Willebrand factor (VWF) responses to desmopressin (DDAVP) and factor VIII/VWF concentrate substitution in von Willebrand disease type 1 and 2.
    van Vliet HH; Kappers-Klunne MC; Leebeek FW; Michiels JJ
    Thromb Haemost; 2008 Sep; 100(3):462-8. PubMed ID: 18766263
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A Mechanistic Model to Quantify von Willebrand Factor Release, Survival and Proteolysis in Patients with von Willebrand Disease.
    Ferrari M; Galvanin F; Barolo M; Daidone V; Padrini R; Bezzo F; Casonato A
    Thromb Haemost; 2018 Feb; 118(2):309-319. PubMed ID: 29378356
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The pathophysiology of von Willebrand disease: therapeutic implications.
    Schneppenheim R
    Thromb Res; 2011; 128 Suppl 1():S3-7. PubMed ID: 22221847
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Biologic response to subcutaneous and intranasal therapy with desmopressin in a large Amish kindred with Type 2M von Willebrand disease.
    Sharthkumar A; Greist A; Di Paola J; Winay J; Roberson C; Heiman M; Herbert S; Parameswaran R; Shapiro A
    Haemophilia; 2008 May; 14(3):539-48. PubMed ID: 18312368
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Abnormal structure of von Willebrand factor in myeloproliferative syndrome is associated to either thrombotic or bleeding diathesis.
    López-Fernández MF; López-Berges C; Martín R; Pardo A; Ramos FJ; Batlle J
    Thromb Haemost; 1987 Aug; 58(2):753-7. PubMed ID: 3499682
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.